The FDA, as part of its drug safety overhaul, could adopt data mining to speed and improve the review of drug safety as new products move into the market, which might ease pressure on the FDA during the pre-market approval process, The RPM Report writes. However, some are worried the tools could lead to an inflated number of safety concerns, dangerous competitive tools and a minimization of FDA power in determining drug safety.

Related Summaries